China NMPA Inspection - Guangzhou Cimei Biotechnology Co., Ltd. - April 10, 2023

The National Medical Products Administration (NMPA) announced on April 10, 2023, the results of recent unannounced inspections involving three cosmetics manufacturers: Guangzhou Ximei Biotechnology Co., Ltd., Guangzhou Shangpin Biotechnology Co., Ltd., and Huizhou Aozi Cosmetics Co., Ltd. These inspections revealed that the companies violated key regulatory frameworks, specifically the "Cosmetics Supervision and Management Regulations" and the "Cosmetics Production Quality Management Standards." The exact nature of the violations was not detailed, but the companies acknowledged the issues. In response, and to ensure public safety, the NMPA has directed the Guangdong Provincial Drug Administration to mandate that these companies immediately suspend all production and operational activities. They are also required to implement comprehensive rectification measures to address the identified non-compliances. Additionally, an official investigation has been initiated into their practices to determine further actions. This highlights the NMPA's commitment to stringent oversight of the cosmetics industry.